[1]
Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 2015; 112(5): 71-81.
[2]
Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf 2017; 15(3): 334-65.
[3]
Hashemi H, Khabazkhoob M, Kheirkhah A, et al. Prevalence of dry eye syndrome in an adult population. Clin Exp Ophthalmol 2014; 42(3): 242-8.
[4]
Bakkar MM, Shihadeh WA, Haddad MF, Khader YS. Epidemiology of symptoms of dry eye disease (DED) in Jordan: A cross-sectional non-clinical population-based study. Cont Lens Anterior Eye 2016; 39(3): 197-202.
[5]
Alshamrani AA, Almousa AS, Almulhim AA, et al. Prevalence and risk factors of dry eye symptoms in a Saudi Arabian population. Middle East Afr J Ophthalmol 2017; 24(2): 67-73.
[6]
Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 2007; 143(3): 409-15.
[7]
Labbé A, Wang YX, Jie Y, Baudouin C, Jonas JB, Xu L. Dry eye disease, dry eye symptoms and depression: The Beijing Eye Study. Br J Ophthalmol 2013; 97(11): 1399-403.
[8]
Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 2011; 30(4): 379-87.
[9]
Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf 2017; 15(3): 575-628.
[10]
Milner MS, Beckman KA, Luchs JI, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol 2017; 27(Suppl. 1): 3-47.
[11]
Tam PM, Young AL, Cheng LL, Lam PT. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant 2010; 45(5): 957-8.
[12]
Sotozono C, Ueta M, Yokoi N. Severe dry eye with combined mechanisms is involved in the ocular sequelae of SJS/TEN at the chronic stage. Invest Ophthalmol Vis Sci 2018; 59(14): DES80-6.
[13]
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf 2017; 15(3): 276-83.
[14]
Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282(15): 1458-65.
[15]
Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Cont Lens Anterior Eye 2010; 33(2): 55-60.
[16]
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol 2000; 118(5): 615-21.
[17]
Abetz L, Rajagopalan K, Mertzanis P, Begley C, Barnes R, Chalmers R. Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes 2011; 9: 111.
[18]
Iyer JV, Lee SY, Tong L. The dry eye disease activity log study. ScientificWorldJournal 2012; 2012589875
[19]
Khurana AK, Choudhary R, Ahluwalia BK, Gupta S. Hospital epidemiology of dry eye. Indian J Ophthalmol 1991; 39(2): 55-8.
[20]
Ousler GW III, Abelson MB, Johnston PR, Rodriguez J, Lane K, Smith LM. Blink patterns and lid-contact times in dry-eye and normal subjects. Clin Ophthalmol 2014; 8: 869-74.
[21]
Rodriguez JD, Ousler GW III, Johnston PR, Lane K, Abelson MB. Investigation of extended blinks and interblink intervals in subjects with and without dry eye. Clin Ophthalmol 2013; 7: 337-42.
[22]
Turu L, Alexandrescu C, Stana D, Tudosescu R. Dry eye disease after LASIK. J Med Life 2012; 5(1): 82-4.
[23]
Uchino M, Schaumberg DA, Dogru M, et al. Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology 2008; 115(11): 1982-8.
[24]
Yang WJ, Yang YN, Cao J, et al. Risk factors for dry eye syndrome: a retrospective case-control study. Optom Vis Sci 2015; 92(9): e199-205.
[25]
Nguyen CQ, Peck AB. Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease. Ocul Surf 2009; 7(1): 11-27.
[26]
Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol (Copenh) 1983; 61(1): 108-16.
[27]
Xu L, Zhang W, Zhu XY, Suo T, Fan XQ, Fu Y. Smoking and the risk of dry eye: a Meta-analysis. Int J Ophthalmol 2016; 9(10): 1480-6.
[28]
Alves M, Angerami RN, Rocha EM. Dry eye disease caused by viral infection: review. Arq Bras Oftalmol 2013; 76(2): 129-32. [review].
[29]
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf 2017; 15(3): 539-74.
[30]
Bron AJ, Argüeso P, Irkec M, Bright FV. Clinical staining of the ocular surface: mechanisms and interpretations. Prog Retin Eye Res 2015; 44: 36-61.
[31]
Adil MY, Xiao J, Olafsson J, et al. Meibomian gland morphology is a sensitive early indicator of meibomian gland dysfunction. Am J Ophthalmol 2019; 200: 16-25.
[32]
Johnston PR, Rodriguez J, Lane KJ, Ousler G, Abelson MB. The interblink interval in normal and dry eye subjects. Clin Ophthalmol 2013; 7: 253-9.
[33]
Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17(5): 350-5.
[34]
Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf 2017; 15(3): 511-38.
[35]
Najafi L, Malek M, Valojerdi AE, et al. Dry eye and its correlation to diabetes microvascular complications in people with type 2 diabetes mellitus. J Diabetes Complications 2013; 27(5): 459-62.
[36]
Ayaki M, Tsubota K, Kawashima M, Kishimoto T, Mimura M, Negishi K. Sleep disorders are a prevalent and serious comorbidity in dry eye. Invest Ophthalmol Vis Sci 2018; 59(14): DES143-50.
[37]
Mastrota KM. Impact of floppy eyelid syndrome in ocular surface and dry eye disease. Optom Vis Sci 2008; 85(9): 814-6.
[38]
Hayirci E, Yagci A, Palamar M, Basoglu OK, Veral A. The effect of continuous positive airway pressure treatment for obstructive sleep apnea syndrome on the ocular surface. Cornea 2012; 31(6): 604-8.
[39]
Zeev MS, Miller DD, Latkany R. Diagnosis of dry eye disease and emerging technologies. Clin Ophthalmol 2014; 8: 581-90.
[40]
Denoyer A, Landman E, Trinh L, Faure JF, Auclin F, Baudouin C. Dry eye disease after refractive surgery: comparative outcomes of small incision lenticule extraction versus LASIK. Ophthalmology 2015; 122(4): 669-76.
[41]
Akpek EK, Klimava A, Thorne JE, Martin D, Lekhanont K, Ostrovsky A. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea 2009; 28(5): 493-7.
[42]
Prasad S, Galetta SL. Eye movement abnormalities in multiple sclerosis. Neurol Clin 2010; 28(3): 641-55.
[43]
Gürdal C, Saraç O, Genç I, Kırımlıoğlu H, Takmaz T, Can I. Ocular surface and dry eye in Graves’ disease. Curr Eye Res 2011; 36(1): 8-13.
[44]
Kim YS, Kwak AY, Lee SY, Yoon JS, Jang SY. Meibomian gland dysfunction in Graves’ orbitopathy. Can J Ophthalmol 2015; 50(4): 278-82.
[45]
Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 2003; 22(3): 230-3.
[46]
Li M, Gong L, Chapin WJ, Zhu M. Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci 2012; 53(9): 5722-7.
[47]
Um SB, Yeom H, Kim NH, Kim HC, Lee HK, Suh I. Association between dry eye symptoms and suicidal ideation in a Korean adult population. PLoS One 2018; 13(6)e0199131
[48]
Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. Cornea 2006; 25(8): 900-7.
[49]
Baudouin C, Aragona P, Van Setten G, et al. Diagnosing the severity of dry eye: A clear and practical algorithm. Br J Ophthalmol 2014; 98(9): 1168-76.
[50]
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf 2017; 15(3): 438-510.
[51]
Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev 2016; 2CD009729
[52]
Deng R, Su Z, Hua X, Zhang Z, Li DQ, Pflugfelder SC. Osmoprotectants suppress the production and activity of matrix metalloproteinases induced by hyperosmolarity in primary human corneal epithelial cells. Mol Vis 2014; 20: 1243-52.
[53]
Corrales RM, Luo L, Chang EY, Pflugfelder SC. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea 2008; 27(5): 574-9.
[54]
Chiambaretta F, Doan S, Labetoulle M, et al. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol 2017; 27(1): 1-9.
[55]
Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000; 118(11): 1489-96.
[56]
Chen M, Gong L, Sun X, et al. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial. J Ocul Pharmacol Ther 2010; 26(4): 361-6.
[57]
Sacchetti M, Mantelli F, Lambiase A, Mastropasqua A, Merlo D, Bonini S. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol 2014; 98(8): 1016-22.
[58]
Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999; 106(4): 811-6.
[59]
Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens 2014; 40(5): 289-96.
[60]
Jonisch J, Steiner A, Udell IJ. Preservative-free low-dose dexamethasone for the treatment of chronic ocular surface disease refractory to standard therapy. Cornea 2010; 29(7): 723-6.
[61]
Lee HK, Ryu IH, Seo KY, Hong S, Kim HC, Kim EK. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology 2006; 113(2): 198-205.
[62]
Lin T, Gong L. Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: A randomized clinical trial in China. Medicine (Baltimore) 2015; 94(7)e551
[63]
Goto E, Yagi Y, Kaido M, Matsumoto Y, Konomi K, Tsubota K. Improved functional visual acuity after punctal occlusion in dry eye patients. Am J Ophthalmol 2003; 135(5): 704-5.
[64]
Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010; (9): CD006775
留言 (0)